Given that CA125 is historically non-informative in ~20% of women with ovarian cancer at the time of their initial diagnosis, we also sought to compare the sensitivity of IGFBP-4 to that of CA125 [20]. This evidence concerns the gene IGFBP4 and ovarian carcinoma.